Skip to main content

Table 4 Availability of measurements in the recruited patient dataset

From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Potential covariate Availability (number of patients, out of 54)
Age 54
Breslow thickness 43
LDH 51
LY% 53
SOD at the baselinea 54
Cutaneous malignant melanoma (Y/N) 52
Nodular melanoma (Y/N) 52
BRAF V600 mutation (Y/N) 46
  1. Measurements of parameters that are potential covariates for determination of the personal models (Y/N refers to a test outcome)
  2. aSum of diameters of measurable lesions at the baseline, as defined by RECIST 1.1 [40]